Clinical trials for Mucolipidosis type II
24 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPHASE1, PHASE2NCT07012031Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationNational Cancer Institute (NCI) · PI: Andreas N Saltos
- RECRUITINGPhase 1NCT07377435DC/MM Fusion Vaccine With BCMA CAR-T in R/R MMDavid Avigan · PI: Jacalyn Rosenblatt, MD
- RECRUITINGPhase 1NCT07032714Mezigdomide and Talquetamab in Relapsed and Refractory Multiple MyelomaMassachusetts General Hospital · PI: Andrew J. Yee, MD
- RECRUITINGPHASE1, PHASE2NCT06903377Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerSuzhou Zelgen Biopharmaceuticals Co.,Ltd · PI: Jason Wu
- RECRUITINGPhase 1NCT06994143A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid ArthritisCullinan Therapeutics Inc.
- RECRUITINGPhase 1NCT06861543The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)Peking Union Medical College Hospital · PI: Wenming Wu, PhD
- RECRUITINGPHASE1, PHASE2NCT06083207A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaInnovent Biologics (Suzhou) Co. Ltd.
- RECRUITINGPHASE1, PHASE2NCT06495723Polyspecific Antibodies in Lymphoproliferative T-cell DisordersXenothera SAS · PI: Gandhi-Laurent DAMAJ, MD
- RECRUITINGPhase 1NCT06375187A Study of GC203 TIL in Advanced Malignant Solid TumorsShanghai Juncell Therapeutics
- RECRUITINGPhase 1NCT06080191Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALLBambino Gesù Hospital and Research Institute · PI: Franco Locatelli, MD, PhD
- RECRUITINGPhase 1NCT06403735A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid TumorsQilu Pharmaceutical Co., Ltd.
- RECRUITINGN/ANCT05292521Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung CancerRoswell Park Cancer Institute · PI: Anurag K Singh
- RECRUITINGPhase 1NCT06121557Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · PI: Erwei Song, M.D., Ph.D.
- RECRUITINGPhase 1NCT05968690Naltrexone and Propranolol Combined With ImmunotherapySarah Weiss · PI: Sarah Weiss, MD
- RECRUITINGPHASE1, PHASE2NCT05501665Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerVanderbilt-Ingram Cancer Center · PI: Evan Osmundson, MD, PhD
- RECRUITINGNCT05887011CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in RussiaAstraZeneca
- RECRUITINGPhase 1NCT05656573CART-PSMA Cells for Advanced Prostate CancerNova Therapeutics LLC · PI: Jay Zhang
- RECRUITINGPHASE1, PHASE2NCT05549609A Study of XSTEM-VLU in Patients With Difficult-to-heal Venous Leg UlcersXintela AB · PI: Folke Sjöberg
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04743505Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Washington University School of Medicine · PI: Anjali Rohatgi, M.D., Ph.D.
- RECRUITINGPhase 2NCT04585477Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)Stanford University · PI: Joel W Neal, MD,PhD
- ACTIVE NOT RECRUITINGNCT04574635Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical CancerMayo Clinic · PI: Allison E. Garda, MD
- RECRUITINGEarly Phase 1NCT05060796Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLCSecond Affiliated Hospital of Guangzhou Medical University · PI: Zhenfeng Zhang, MD, PHD
- RECRUITINGPHASE1, PHASE2NCT03190941Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsNational Cancer Institute (NCI) · PI: James C Yang, M.D.
- ACTIVE NOT RECRUITINGPhase 1NCT02442297T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS TumorsBaylor College of Medicine · PI: Nabil M Ahmed, MD